Herantis Pharma Provides R&D Update and Information About New Biomarker Program
Herantis Pharma Plc, Press Release, 26 October 2021 at 08:00 EEST Herantis Pharma Plc (“Herantis or the Company”), focusing on disease modifying therapies for debilitating neurodegenerative diseases, today hosts a live webinar providing an R&D update at 11:00 EEST/10:00 CEST with the company’s CSO, Dr. Henri Huttunen and COO, Antti Vuolanto. Highlights: · Launch of Herantis’ novel biomarker-based program for our disease modifying assets · Strong data on impact of rhCDNF on disease biomarkers including an update on clinical follow-up study · Data on successful and impressive